Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.

Abstract

The new combined oral contraceptive containing ethinyl estradiol and drospirenone has the potential for improving a woman's quality of life. Drospirenone's antiandrogenic activity, for example, makes it effective in reducing acne and seborrhea. The majority of reproductive-age women suffer from some degree of premenstrual symptomatology. In some cases, these monthly symptoms are severe enough to negatively impact a woman's quality of life. Drospirenone's antimineralocorticoid activity aids in reducing some of the most bothersome symptoms associated with the premenstrual phase of the menstrual cycle.

• Authors: Vivian Dickerson
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 47 Issue 11 Suppl Pg. 985-93 (Nov 2002) ISSN: 0024-7758 [Print] United States
• PMID: 12497673 (Publication Type: Journal Article, Review)

Chemical References

• Androgen Antagonists
• Androstenes
• Contraceptives, Oral, Combined
• Mineralocorticoids
• Progesterone Congeners
• Ethinyl Estradiol
• drospirenone

Topics

• Acne Vulgaris (drug therapy)
• Androgen Antagonists
• Androstenes (administration & dosage, therapeutic use)
• Contraceptives, Oral, Combined
• Ethinyl Estradiol (administration & dosage)
• Female
• Humans
• Mineralocorticoids (antagonists & inhibitors)
• Premenstrual Syndrome (drug therapy)
• Progesterone Congeners (administration & dosage, therapeutic use)
• Quality of Life
• Randomized Controlled Trials as Topic
• Weight Gain